We’ve recently updated our valuation analysis.

CareTrust REIT Valuation

Is CTRE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CTRE?

Other financial metrics that can be useful for relative valuation.

CTRE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.1x
Enterprise Value/EBITDA17.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CTRE's PS Ratio compare to its peers?

The above table shows the PS ratio for CTRE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average8.4x
CVMC.A Sila Realty Trust
8.2xn/aUS$1.5b
LTC LTC Properties
9.8x4.3%US$1.6b
NHI National Health Investors
8.9x10.6%US$2.5b
DOC Physicians Realty Trust
6.8x5.1%US$3.7b
CTRE CareTrust REIT
10.1x8.9%US$2.0b

Price-To-Sales vs Peers: CTRE is expensive based on its Price-To-Sales Ratio (10.1x) compared to the peer average (8.4x).


Price to Earnings Ratio vs Industry

How does CTRE's PE Ratio compare vs other companies in the US REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a4.4%
n/an/an/a

Price-To-Sales vs Industry: CTRE is expensive based on its Price-To-Sales Ratio (10.1x) compared to the US REITs industry average (5x)


Price to Sales Ratio vs Fair Ratio

What is CTRE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CTRE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.1x
Fair PS Ratio9.7x

Price-To-Sales vs Fair Ratio: CTRE is expensive based on its Price-To-Sales Ratio (10.1x) compared to the estimated Fair Price-To-Sales Ratio (9.7x).


Share Price vs Fair Value

What is the Fair Price of CTRE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CTRE ($20.23) is trading below our estimate of fair value ($41.19)

Significantly Below Fair Value: CTRE is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CTRE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$20.23
US$20.83
+3.0%
9.3%US$24.00US$18.00n/a9
Nov ’23US$18.56
US$20.67
+11.4%
10.0%US$24.00US$18.00n/a9
Oct ’23US$18.11
US$22.25
+22.9%
7.6%US$24.00US$19.00n/a10
Sep ’23US$21.23
US$22.35
+5.3%
7.6%US$24.00US$19.00n/a10
Aug ’23US$21.06
US$20.75
-1.5%
9.5%US$24.00US$17.00n/a10
Jul ’23US$19.05
US$20.85
+9.4%
10.3%US$24.00US$17.00n/a10
Jun ’23US$18.60
US$21.33
+14.7%
10.1%US$24.00US$17.00n/a9
May ’23US$16.21
US$21.33
+31.6%
10.1%US$24.00US$17.00n/a9
Apr ’23US$19.87
US$22.11
+11.3%
8.1%US$25.00US$19.00n/a9
Mar ’23US$17.12
US$22.80
+33.2%
11.2%US$27.00US$19.00n/a10
Feb ’23US$20.85
US$24.70
+18.5%
6.8%US$27.00US$22.00n/a10
Jan ’23US$22.83
US$25.00
+9.5%
6.0%US$27.00US$22.00n/a9
Dec ’22US$20.00
US$25.00
+25.0%
6.0%US$27.00US$22.00US$19.889
Nov ’22US$21.11
US$25.67
+21.6%
6.4%US$29.00US$23.00US$18.569
Oct ’22US$20.62
US$26.39
+28.0%
5.8%US$29.00US$24.00US$18.119
Sep ’22US$22.35
US$26.39
+18.1%
5.8%US$29.00US$24.00US$21.239
Aug ’22US$24.12
US$26.50
+9.9%
3.3%US$28.00US$25.00US$21.069
Jul ’22US$23.65
US$25.95
+9.7%
4.6%US$27.50US$23.00US$19.0510
Jun ’22US$23.92
US$25.85
+8.1%
5.6%US$27.50US$22.00US$18.6010
May ’22US$24.18
US$25.25
+4.4%
5.5%US$27.50US$22.00US$16.2110
Apr ’22US$24.28
US$25.25
+4.0%
5.5%US$27.50US$22.00US$19.8710
Mar ’22US$22.82
US$24.15
+5.8%
7.1%US$26.50US$22.00US$17.1210
Feb ’22US$23.28
US$23.75
+2.0%
6.6%US$26.50US$22.00US$20.8510
Jan ’22US$22.18
US$22.95
+3.5%
8.7%US$26.50US$19.00US$22.8310
Dec ’21US$20.28
US$21.33
+5.2%
6.6%US$24.00US$19.00US$20.009

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies